92 related articles for article (PubMed ID: 10071042)
1. Inhibition of complement-mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin.
Kojima T; Del Carpio CA; Tajiri H; Yoshikawa K; Saga S; Yokoyama I
Transplantation; 1999 Feb; 67(4):637-8. PubMed ID: 10071042
[TBL] [Abstract][Full Text] [Related]
2. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
Kovacs H; Campbell ID; Strong P; Johnson S; Ward FJ; Reid KB; Eggleton P
Biochemistry; 1998 Dec; 37(51):17865-74. PubMed ID: 9922153
[TBL] [Abstract][Full Text] [Related]
3. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
Wright A; Morrison SL
J Exp Med; 1994 Sep; 180(3):1087-96. PubMed ID: 8064227
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G.
Lukas TJ; Muñoz H; Erickson BW
J Immunol; 1981 Dec; 127(6):2555-60. PubMed ID: 7299136
[TBL] [Abstract][Full Text] [Related]
5. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
6. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
7. Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen.
Mizutani R; Igarashi T; Tanaka T; Shimada I; Arata Y
J Immunol; 1993 Jan; 150(1):131-8. PubMed ID: 8417119
[TBL] [Abstract][Full Text] [Related]
8. Complement interaction with immune serum globulin and immune globulin intravenous.
Bing DH
Am J Med; 1984 Mar; 76(3A):19-24. PubMed ID: 6424450
[TBL] [Abstract][Full Text] [Related]
9. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
10. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease.
Sun H; Olsen HS; Mérigeon EY; So E; Burch E; Kinsey S; Papadimitriou JC; Drachenberg CB; Bentzen SM; Block DS; Strome SE; Zhang X
J Autoimmun; 2017 Nov; 84():97-108. PubMed ID: 28830653
[TBL] [Abstract][Full Text] [Related]
12. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
Brüggemann M; Teale C; Clark M; Bindon C; Waldmann H
J Immunol; 1989 May; 142(9):3145-50. PubMed ID: 2496159
[TBL] [Abstract][Full Text] [Related]
13. Mapping of amino acid residues in the C mu 3 domain of mouse IgM important in macromolecular assembly and complement-dependent cytolysis.
Arya S; Chen F; Spycher S; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1994 Feb; 152(3):1206-12. PubMed ID: 8301125
[TBL] [Abstract][Full Text] [Related]
14. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
15. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
Butko P; Nicholson-Weller A; Wessels MR
J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
Russell MW; Reinholdt J; Kilian M
Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
[TBL] [Abstract][Full Text] [Related]
17. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
Lint TF; Behrends CL; Baker PJ; Gewurz H
J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
[TBL] [Abstract][Full Text] [Related]
18. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q.
Kishore U; Leigh LE; Eggleton P; Strong P; Perdikoulis MV; Willis AC; Reid KB
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):27-32. PubMed ID: 9639558
[TBL] [Abstract][Full Text] [Related]
20. Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.
Okada M; Utsumi S
J Immunol; 1989 Jan; 142(1):195-201. PubMed ID: 2491872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
